Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,132,454
  • Shares Outstanding, K 292,300
  • Annual Sales, $ 191,450 K
  • Annual Income, $ -70,220 K
  • 36-Month Beta 1.93
  • Price/Sales 32.55
  • Price/Cash Flow 0.00
  • Price/Book 68.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.63 +6.88%
on 04/06/17
21.92 -4.29%
on 03/28/17
+0.54 (+2.64%)
since 03/21/17
3-Month
16.72 +25.48%
on 01/31/17
23.49 -10.69%
on 02/21/17
+3.06 (+17.08%)
since 01/20/17
52-Week
4.25 +393.65%
on 05/05/16
23.49 -10.69%
on 02/21/17
+16.46 (+364.16%)
since 04/21/16

Most Recent Stories

More News
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 26,750 shares of Exelixis common stock and stock options to purchase...

EXEL : 20.98 (-1.59%)
Exelixis Shares Up 17.0% Since SmarTrend's Buy Recommendation (EXEL)

SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on January 10th, 2017 at $18.15. In approximately 3 months, Exelixis has returned 16.97% as of today's recent price of $21.24.

EXEL : 20.98 (-1.59%)
Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has repaid all amounts outstanding under its term loan with Silicon Valley Bank initiated in 2010 and which was due for repayment on May...

EXEL : 20.98 (-1.59%)
Exelixis to Present at the Needham & Company Healthcare Conference on April 4

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at the 16th Annual...

EXEL : 20.98 (-1.59%)
Look for Shares of Exelixis to Potentially Pullback after Yesterday's 3.68% Rise

Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $21.59 to a high of $22.69. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $22.19...

EXEL : 20.98 (-1.59%)
Biotech Stocks Under Scanner -- Gilead Sciences, Exelixis, Mast Therapeutics, and Novavax

Biotechnology is this morning's featured industry on Stock-Callers.com, and aligned for assessment are these for equities: Gilead Sciences Inc. (NASDAQ: GILD), Exelixis Inc. (NASDAQ: EXEL), Mast Therapeutics...

EXEL : 20.98 (-1.59%)
GILD : 65.93 (-0.86%)
NVAX : 0.83 (+1.22%)
MSTX : 0.13 (unch)
Uptrend Call Working As Exelixis Stock Rises 23.8% (EXEL)

SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on January 10th, 2017 at $18.15. In approximately 2 months, Exelixis has returned 23.77% as of today's recent price of $22.47.

EXEL : 20.98 (-1.59%)
Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma...

EXEL : 20.98 (-1.59%)
After Yesterday's Rally of 3.96% Shares Could Potentially Pullback

Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $21.95 to a high of $22.93. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $22.80...

EXEL : 20.98 (-1.59%)
Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland

Upcoming AWS Coverage on Exelixis Post-Earnings Results

EXEL : 20.98 (-1.59%)
ICPT : 107.89 (+0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Support & Resistance

2nd Resistance Point 22.15
1st Resistance Point 21.57
Last Price 20.98
1st Support Level 20.67
2nd Support Level 20.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.